According to a new report from Eli Lilly, the average list price on its insulin drug, Humalog U100, posted a 52 percent increase (more than $200) between 2014 to mid-2017.
The average price the drugmaker realized per patient, according to a BioPharma Dive report, dropped about 8 percent in the same time frame.
Lilly earlier this month said it would be offering an authorized generic of the drug at half the current list price.
“Those not well-served by the current system will have a better, more affordable option — which can also count toward their deductible,” Lilly wrote in the report. “But patients with health plans that prefer the current system won’t see any changes — Humalog will remain available.”
According to the BioPharma Dive report, Lilly also said it will in its TV ads direct viewers to a website where they can discover more pricing information on its drugs.
To read the full report on BioPharma Dive, click here.